No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
The concept of contract research organizations started positively, wuxi bio (02269) rose by 13.03%, and the U.S. Biosafety Act was not included in the 2025 Fiscal Year Defense Authorization Act.
Jinwu Financial News | The contract research organizations concept started off positively, as of the time of publication, Wuxi Bio (02269) is up 13.03%, Wuxi AppTec (02359) is up 11.72%, Pharmaron (03759) is up 9.14%, Genscript Bio (01548) is up 4.98%, and Tigermed (03347) is up 4.87%. In terms of news, on December 7 local time in the USA, the final agreement text of the 2025 fiscal year National Defense Authorization Act (NDAA) released by the military committees of both the House and Senate did not include the biosafety act. Morgan Stanley stated, USA
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Trending Industry Today: WUXI APPTEC Leads Gains In CRO Stocks
tigermed (300347.SZ): has cumulatively repurchased 3.6552 million shares.
On December 4, Gelonghui reported that tigermed (300347.SZ) announced that as of November 30, 2024, the company's share repurchase special securities account had cumulatively repurchased 3.6552 million shares of the company through centralized bidding trade, accounting for 0.4226% of the company's total share capital, and 0.4927% of the company's A-shares total share capital, with the highest fill price being 55.30 yuan/share, the lowest fill price being 48.17 yuan/share, and the total amount of the transaction being 0.191 billion yuan (excluding transaction fees).
Do Its Financials Have Any Role To Play In Driving Hangzhou Tigermed Consulting Co., Ltd's (SZSE:300347) Stock Up Recently?
No Data
